Aims Administration of l-arginine by intravenous infusion or via oral absorption has been shown to induce peripheral vasodilation in humans, and to improve endothelium-dependent vasodilation. We investigated the pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of l-arginine after a single intravenous infusion of 30 g or 6 g, or after a single oral application of 6 g, as compared with the respective placebo, in eight healthy male human subjects. Methods l-arginine levels were determined by h.p.l.c. The vasodilator effects of larginine were assessed non-invasively by blood pressure monitoring and impedance cardiography. Urinary nitrate and cyclic GMP excretion rates were measured as non-invasive indicators of endogenous NO production. Results Plasma l-arginine levels increased to (mean±s.e.mean) 6223±407 (range, 5100-7680) and 822±59 (527-955) mmol l −1 after intravenous infusion of 30 g and 6 g l-arginine, respectively, and to 310±152 (118-1219) mmol l −1 after oral ingestion of 6 g l-arginine. Oral bioavailability of l-arginine was 68±9 (51-87)%. Clearance was 544±24 (440-620), 894±164 (470-1190), and 1018±230 (710-2130) ml min −1 , and elimination half-life was calculated as 41.6±2.3 (34-55), 59.6±9.1 (24-98), and 79.5±9.3 (50-121) min, respectively, for 30 g i.v., 6 g i.v., and 6 g p.o. of l-arginine. Blood pressure and total peripheral resistance were significantly decreased after intravenous infusion of 30 g l-arginine by 4.4±1.4% and 10.4±3.6%, respectively, but were not significantly changed after oral or intravenous administration of 6 g l-arginine. l-arginine (30 g) also significantly increased urinary nitrate and cyclic GMP excretion rates by 97±28 and 66±20%, respectively. After infusion of 6 g l-arginine, urinary nitrate excretion also significantly increased, (nitrate by 47±12% [P<0.05], cyclic GMP by 67±47%
Introduction be a suitable non-invasive method to assess NO formation rates in human subjects in vivo [6] [7] [8] . l-arginine is the physiological precursor of nitric oxide (NO), an important mediator of vasodilation and inhibition It has previously been shown that an intravenous infusion of 14-30 g of l-arginine induces vasodilation and inhibition of platelet aggregation via increased formation of cyclic GMP [1] . NO is synthesized in endothelial cells from the of platelet aggregation [6, 8] , and improves acetylcholineinduced, endothelium-dependent vasodilation [9, 10] . In terminal guanidino nitrogen of l-arginine by the activity of the endothelial, calcium-dependent isoform of NO synthase atherosclerotic patients, intravenous infusion of 30 g larginine induces peripheral vasodilation [7] , resulting in [2] . NO is rapidly oxidized to NO adhesiveness for the endothelium [14] in humans. l-arginine as the mean of five measurements during the last 20 min before start of the l-arginine infusion. has also been used for other purposes like stimulation of growth hormone release from the pituitary gland [15] .
Plasma samples were drawn into vacutainers containing sodium EDTA at baseline and 5, 10, 15, 20, 25, 30, 35, 40 , Physiological uptake of l-arginine with usual diets is about 4-6 g day −1 [16]. The daily doses of l-arginine utilized in 45, 60, 90, 150 , and 210 min after the start of the infusion. On the days with capsule intake, time points for plasma these studies significantly exceed physiological uptake of this semi-essential amino acid by 3-8-fold. generation were 0, 30, 60, 90, 150, and 210 min. Subjects came back to the laboratory on the next morning when However, few data are known on the pharmacokinetic parameters and the pharmacokinetic-pharmacodynamic additional plasma samples were drawn at 16, 20, and 24 h after drug intake. On the infusion days, urine samples were relationship of l-arginine in humans. One study in healthy human subjects investigated the pharmacokinetics of a multicollected during 1 h immediately before the start of the infusion (baseline), at the end of the infusion (30 min), as amino acid formulation used for the supplementation of polytraumatic patients [17] ; however, the dose of l-arginine well as 60, 120, and 180 min after the start of the infusion. On the days on which the drugs were applied orally, urine which was administered in this study was much lower than the doses used to induce NO-dependent vasodilation or samples were collected during 1 h immediately before drug intake (baseline), as well as 60, 120, 180, and 240 min after growth hormone secretion. To characterize better the pharmacokinetic behaviour of l-arginine in healthy humans drug intake. after acute intravenous and oral administration, we performed a double-blind, placebo-controlled dose-comparison study in healthy human subjects. was determined as its pentafluorobenzyl (PFB) derivative by gas chromatography-mass spectrometry the pharmacokinetic-pharmacodynamic relationship of l-arginine.
(GC-MS) as described previously [18, 19] cadmium (10 min, 20°C). These samples (100 ml) were treated with 400 ml of acetone and 5 ml of PFB bromide, pated in this double-blind, placebo controlled study. All subjects underwent a physical examination and a routine and the mixture was allowed to react for 60 min at 50°C. Acetone was then removed under nitrogen, and reactants laboratory screening ( peripheral blood cell count, serum creatinine, sodium, potassium, chloride, ALT and AST were extracted by vortexing with 1000 ml of toluene. Aliquots (1 ml) thereof were injected into the GC-MS activities) and gave their written informed consent before inclusion into the study. The protocol had previously been instrument. GC-MS was carried out on a Hewlett Packard MS Engine 5989 series II (Waldbronn, Germany). A fusedapproved by the Institutional Review Board for Studies in Humans. The study consisted of 5 study days for each silica capillary column DB-5 MS (30 m×0.25 mm i.d., 0.25 mm film thickness) from J&W Scientific (Rancho subject in randomized sequence with at least 7 days of washout between them. Before each study day, the Cordova, CA) was used with helium as the carrier gas (70 kPa). Negative ions were produced by chemical ionizparticipants were subjected to a standardized diet with a reduced nitrate content (~32 mg nitrate day −1 ) for 24h. ation using methane as the reactant gas (200 Pa) at an electron energy of 230 eV and an electron current of On each day, they received either an intravenous infusion of l-arginine (30 g or 6 g l-arginine-hydrochloride 300 mA. Quantitation was performed by selected ion monitoring at m/z 46 for endogenous NO − 2 /NO − 3 and (Fresenius, Bad Homburg, Germany) dissolved in 150 ml of physiological saline) or placebo (150 ml of physiological m/z 47 for the internal standard. The detection limit of the method was 20 fmol nitrate. Intra-and interassay variabilities saline) during 30 min, or 6 g l-arginine or placebo (12 capsules of 0.5 g of l-arginine-hydrochloride or lactose).
were below 3.8%. For the determination of cGMP, urine samples were At the beginning of each study day the subjects emptied their bladder. Mild oral volume loading with herb tea (using diluted 15500 in phosphate buffered saline and acetylated by a mixture of acetic acid anhydride/triethylamine. Cyclic demineralized water) was started with 3 ml kg −1 of body weight initially, and continued during the entire study GMP content was measured by radioimmunoassay using [ 125 I]-cGMP as a tracer and globulin precipitation. The period with 1-2 ml kg −1 of body weight h −1 . Self-adhesive ring electrodes were fixed around the thorax and left there detection limit of the assay was 160 fmol ml −1 . Intra-and interassay variabilities were 3.5% and 8.1%, respectively. during the entire study period for continuous registration of the impedance cardiogram (see below). A blood pressure Urinary and plasma creatinine was determined spectrophotometrically with the alkaline picric acid method in an cuff was fixed to the right arm for blood pressure registration. Haemodynamic measurements were started after at least automatic analyzer (Beckman, Galway, Ireland). The urinary excretion rates of NO − 3 and cGMP were corrected by 60 min of adaptation, during which the subjects remained in the supine position. Baseline blood pressure was calculated urinary creatinine concentration in order to limit the variability due to differences in renal excretory function as assessed at the corresponding time points during and after placebo administration from the concentrations obtained described previously [4] .
after l-arginine administration. Pharmacokinetic analysis was performed by use of a one or two compartment model, or
Determination of plasma l-arginine concentrations a non-compartmental body model using nonlinear regression assuming linear kinetics. The model that showed the best Plasma l-arginine concentrations were determined by highperformance liquid chromatography (h.p.l.c.) using prefit to the data was chosen for further analysis. Terminal elimination half-life was calculated by extrapolating lcolumn derivatization with o-phthalaldehyde (OPA) as described previously [20] . Plasma samples and standards were arginine plasma concentrations to infinity using the measured concentration at 24 h after drug intake. Areas under the extracted on CBA solid phase extraction cartridges (Varian, Harbor City, CA, USA). The eluates were dried under concentration-time curves (AUC values) were calculated using the linear trapezoidal rule of the TOPFIT program nitrogen and residues dissolved in double distilled water for h.p.l.c. analysis (Gynkotek, Munich, Germany). Samples and
[24] for data extrapolated to infinity. Oral bioavailability was calculated from comparison of the AUC values for standards were incubated for exactly 30 s with the OPA reagent (5.4 mg ml −1 OPA in borate buffer, pH 8.5, intravenous and oral administration of 6 g of l-arginine. PK/PD analysis was performed on individual plasma lcontaining 0.4% 2-mercaptoethanol) before automatic injection into the h.p.l.c. system. Chromatographic separation arginine/TPR data for the intravenous 30 g dose using a partially nonparametric approach [25, 26] . Changes in TPR was performed on a C 6 H 5 column (Macherey and Nagel, Düren, Germany) with the fluorescence monitor set at l ex = were too small for both administration routes of the 6 g dose to allow PK/PD analysis. As the maximum plasma 340 nm and l em =455 nm. Samples were isocratically eluted from the column with 0.96% citric acid/methanol (251 v/v, concentration and the maximum decrease in TPR occurred almost simultaneously, a model directly linking the effect to pH 6.8) at a flow rate of 1 ml min
. The coefficients of variation of the method had previously been determined as the plasma compartment was chosen. The accuracy of model selection was then verified by testing for the presence of 5.2% within-assay and 5.5% between-assay; the detection limit of the assay was 0.1 mmol l −1 . hysteresis in the sequential concentration-versus-effect plot.
Haemodynamic measurements Calculations and statistics
Data are given as mean±s.e.mean Statistical significance Systemic arterial blood pressure was measured by the standard sphygmomanometric method using an automatic was tested using analysis of variance followed by Fisher's protected least significant difference test for comparisons device (Boso digital II, Bosch und Sohn, Jungingen, Germany). Non-invasive determination of cardiac output between the treatment groups. Linear regression curves and correlation coefficients were obtained by the least squares (CO) was performed by impedance cardiography [21] . The patients were attached to an impedance cardiograph as method. Statistical significance was accepted at the 0.05 level of probability. described by Belardinelli et al. [22] . Briefly, a constant sinusoidal alternating current (100 MHz, 4 mA) was applied between two thoracic electrodes placed on the level of the Results jugular fossa and lower chest. The associated voltage is detected by two inner electrodes positioned 5 cm apart from Urinary nitrate and cyclic GMP excretion rates the outer electrode pair and parallel to the current path. This voltage is transmitted to an amplifier and a thoracic Baseline hourly urinary nitrate and cyclic GMP excretion rates were 68.7±4.7 mmol mmol −1 creatinine and impedance signal is produced. Thoracic impedance was registered from beat to beat with an impedance cardiograph 30.1±1.6 nmol mmol −1 creatinine, respectively. There were no significant differences at baseline between the 5 (BMT, Stuttgart, Germany) and transferred online to an IBM-compatible computer. Data analysis was performed study days. Infusion of 30 g l-arginine induced a maximum increase in urinary nitrate excretion by 96.5±28.4% and in offline using 5 min mean values. Stroke volume was automatically calculated for each heartbeat according to the cyclic GMP excretion by 65.8±20.0% (each P<0.05 vs baseline; Figure 1 ). Infusion of 6 g l-arginine resulted in equation described by Kubicek et al. [21] . There is good correlation of intraindividual changes in cardiac output maximum increases 46.8±11.7% in nitrate ( P<0.05), but a highly variable and not statistically significant response in obtained by impedance cardiography and echo-Doppler cardiography [23] . Total peripheral resistance was calculated cyclic GMP excretion (66.9±46.6%, P=NS). These maximum increases in urinary nitrate and cyclic GMP excretion as TPR=80×(mean blood pressure)/CO [dyn s cm −5 ].
Baseline values were calculated as the mean of all measurerates were noted in urines collected from 0-30 min after intravenous infusion of l-arginine. The respective maximum ments during the last 20 min prior to the start of l-arginine infusion or oral l-arginine intake.
increases in nitrate and cyclic GMP after oral administration of 6 g l-arginine were also highly variable and not statistically significant (32.1±18.0% and 31.8±36.3% respectively each, Pharmacokinetic and pharmacokinetic/-dynamic ( PK/PD) P=NS vs baseline). After oral l-arginine, peak urinary analysis nitrate excretion was observed in urines collected from 60-120 min, and peak urinary cyclic GMP excretion was l-arginine plasma concentration-time curves were constructed by subtracting baseline fasting l-arginine levels as observed in urines collected from 30-60 min. Urinary at t max =30 min. Peak plasma l-arginine concentrations After intravenous infusion, urinary nitrate and cyclic GMP excretion rates peaked in the first urine sample after were 822±59 mmol l −1 at t max =22 min after infusion of 6 g l-arginine, and 310±152 mmol l −1 at t max =90 min the end of the infusion (30 min), whereas after oral larginine administration, the peak in urinary nitrate excretion after oral administration of 6 g l-arginine. Figure 4 shows the time course of mean l-arginine plasma concentrations was delayed until 120 min after intake (Figure 1) .
after the three different dosages of l-arginine. Pharmacokinetic data analysis was performed after allowing Haemodynamic effects of l-arginine for baseline l-arginine concentrations determined at the same time points during and after placebo administration. Infusion of 30 g l-arginine significantly reduced diastolic (maximum, −9.0±2.3 mm Hg; P<0.05) and systolic Pharmacokinetic data for l-arginine were best described by a non-compartmental model (r=0.993); they are given blood pressure (maximum, −9.2±1.8 mm Hg; P<0.05; Figure 2 ), but induced only minor changes in heart rate. 6 g in Table 1 . There was evidence for nonlinear pharmacokinetics, as evidenced by a dose-dependent elimination half l-arginine had no significant effect on diastolic or systolic blood pressure, neither after intravenous nor after oral life (42±2 min, 60±9 min, and 76±9 min for 30 g i.v., 6 g i.v., and 6 g p.o., respectively). Moreover, AUC (0, 2) administration. Neither intravenous nor oral placebo had any significant effects on blood pressure and heart rate.
values showed a proportional increase with increasing doses of l-arginine (r=0.975, P<0.05). Comparison of AUC for Impedance cardiographic measurements showed a significant increase in cardiac output after 30 g l-arginine, but no intravenous and oral administration of 6 g l-arginine revealed that l-arginine was incompletely bioavailable after oral significant changes after 6 g l-arginine or placebo (Figure 3a) . Total peripheral resistance significantly decreased after administration; absolute bioavailability of oral l-arginine was 68±9%. intravenous infusion of 30 g l-arginine, but showed no concentration (r=0.993). There was also a significant linear correlation between urinary nitrate excretion rates and plasma l-arginine concentrations at midpoint of the urine sampling interval (r=0.604, P<0.05). The mean plasma concentration-effect relationship for intravenous infusion of 30 g l-arginine is shown in Figure 5b . No hysteresis was present in the plasma concentration-effect plot. The equilibration half-life between the l-arginine plasma concentration and effect was calculated to be 5.8±2.3 min.
Discussion
The salient findings of our study are that l-arginine concentration-dependently induces vasodilation in healthy Pharmacokinetic analysis showed evidence for dose-related kinetics of l-arginine. Oral bioavailability of l-arginine is about 70%, and the maximum plasma concentration reached Pharmacokinetic-pharmacodynamic relationship after oral ingestion of l-arginine is considerably lower than after intravenous infusion, due to the delay in absorption The temporal pattern of the changes in l-arginine plasma concentration was closely mirrored in the time course of from the intestinal tract. In PK/PD analysis there is evidence for a direct link between the vasodilator effect of l-arginine the changes in urinary nitrate excretion and total peripheral resistance after the infusion of 30 g l-arginine (Figure 5a) . and its plasma concentration.
We and others have previously demonstrated that lThe relationship between pharmacokinetic and -dynamic data were best described using a linear effect model in arginine induces peripheral vasodilation during intravenous infusion in healthy human subjects [6, 8, 27] . Similar vasodilation may involve stimulation of endogenous, endothelial NO formation, as suggested by studies in which the vasoactive effects of a single intravenous infusion of larginine have also been observed in patients with hypercholeurinary excretion rate of nitrate, the final oxidative metabolite of NO, was increased [6, 8] . The present study sterolaemia [9] and coronary [10] or generalized atherosclerosis [7] . In several studies, l-arginine has also been used in further supports this hypothesis, as we found a close linear relationship between l-arginine plasma levels and urinary an oral dosage form in patients with cardiovascular diseases. Clarkson et al. [12] found improved endothelium-dependent nitrate excretion rates. In other studies, increased exhalation of NO was reported as an indicator for enhanced endogenous brachial artery vasodilation after 4 weeks of 21 g day −1 of oral l-arginine in hypercholesterolaemic subjects. Adams NO formation after l-arginine administration [29] . We here report that the urinary excretion rates of nitrate and cGMP, et al. [14] administered 21 g l-arginine day −1 for 3 days to young patients with coronary artery disease; they found two index molecules for endogenous NO formation in vivo [4] , are increased in a dose-related manner after intravenous improved endothelium-dependent vasodilation and reduced monocyte adhesion after l-arginine as compared with infusion of l-arginine. The maximum elevation of urinary nitrate and cGMP excretion rates occurred within 30-60 min placebo. Rector et al.
[28] gave 5.6 to 12.6 g day −1 of larginine during 6 weeks to patients with heart failure and after the end of l-arginine infusion [6, 7] . 90 min after the end of the infusion, these index metabolites had returned to found significantly improved limb blood flow and functional performance of the patients during exercise testing. Although the basal range again. The hypothesis that l-arginine induces NO elaboration l-arginine has been applied intravenously or orally in these and other studies in patients, the pharmacokinetic data of lby the endothelium and thereby causes vasodilation is in agreement with the present observation of a direct link arginine are largely unknown. Investigation of the oral bioavailability of l-arginine as well as its pharmacokinetics between l-arginine plasma levels and vasodilation. Endothelial NO synthase is continuously stimulated by shear are an important basis for further clinical studies.
In the present study, the temporal pattern of l-arginine stress induced by the blood streaming along the endothelial surface [30] . NO is released from the endothelium almost plasma concentration closely corresponded to the temporal pattern of its vasodilator effect, i.e., the reduction in total instantaneously after stimulation, and NO itself has a very short biological half-life in the range of a few seconds [31] . peripheral resistance and blood pressure. Pharmacokinetic/ pharmacodynamic modelling indicated that the effect It is rapidly inactivated by oxidation to nitrite and nitrate [3, 4] . These biochemical observations correspond well to (reduction in TPR) was directly linked to l-arginine plasma concentration, Alternative models using an indirect link of the results of the biochemical measurements performed in the present study. We found that the elevation of urinary the effect, e.g. to a tissue compartment, or using a separate effect compartment, less closely represented the data. The nitrate excretion corresponded closely to the time pattern of l-arginine plasma levels, as did the change in urinary presence of a direct link between l-arginine plasma levels and its haemodynamic effect was further confirmed by the excretion of the second messenger, cyclic GMP, and the haemodynamic response. lack of hysteresis in the concentration-effect plot. A counterclockwise hysteresis loop would have been expected
The fact that l-arginine increases NO release in vivo has been called the 'l-arginine paradox', because compared with if a delay in equilibration between plasma l-arginine concentration and its concentration at the effect site would the K m value of the endothelial NO synthase (~2.9 mm [39] ) physiological fasting l-arginine plasma levels should be have occurred, if a metabolite of l-arginine would be responsible for the effect, or it the effect would be mediated high enough to saturate the enzyme with substrate [16] . This paradox may be resolved by several observations: by an indirect mechanism like protein synthesis [25] . This, taken together with the short equilibration half-life between Firstly, the K m value was determined in vitro in a crude enzyme preparation [32] ; in vivo, however, factors like l-arginine plasma concentration and the effect, suggests a direct vasodilator action of l-arginine within the vasculature.
intracellular compartmentalization of l-arginine and NO synthase may differ, potentially reducing the availability of The mechanism by which exogenous l-arginine induces substrate for the enzyme. Moreover, the presence of
The rate of utilization of l-arginine after absorption in the splanchnic region and the factors affecting it are of endogenous compounds competing with l-arginine for the enzyme binding site may also cause relative substrate considerable interest, since l-arginine uptake and metabolism in the liver may affect systemic bioavailability of this amino depletion. One such endogenous competitive inhibitor is asymmetric dimethylarginine (ADMA); it has been reported acid. There is evidence that the activity of the l-arginine uptake mechanism (y + -transporter for basic amino acids) is to be present in human plasma [33] and in cultured human endothelial cells [34, 35] . Whether ADMA downregulates low in hepatocytes as compared with other cell types [46] . Accordingly, Felig & Wahren [47] found no concentration NO elaboration in healthy humans, in whom ADMA plasma levels are low [33, 36] , remains undetermined. gradient between the portal and hepatic vein in the postabsorptive state. Taken together, these studies suggest Finally, l-arginine uptake may be a crucial step limiting intracellular l-arginine availability in vivo [37] .
that l-arginine metabolism in the liver is functionally separated from whole-body l-arginine metabolism. Blanchier Besides stimulating NO production, l-arginine is known to exert other effects which may contribute to its et al. [48] showed that a minor part of an oral l-arginine dose administered to healthy rats is metabolized by vasodilator properties, like stimulation of growth hormone secretion [15] and insulin release [27] . However, the peak enterocytes. These findings may explain why the majority of an orally administered l-arginine dose was systemically in growth hormone secretion after l-arginine infusion occurs later than the peak in vasodilation [own, unpublished available in the present study. Even outside the liver, larginine can be a substrate for several metabolic pathways: observation]. Interestingly, these endocrine effects of larginine may may also cause secondary increases in NO Ingested arginine can be a source of ornithine in the intestine [49] ; it may serve to replenish arginine which is release: Many of the physiological effects of growth hormone have been shown to occur via local production lost during hepatic urea synthesis [50] ; it may undergo decarboxylation to agmatine in the kidney and the brain of IGF-1 [38] , which in turn induces endotheliumdependent vasodilation that can be blocked by NO synthase
[51], or be used by the NO synthase to generate NO and citrulline [52] . 15 N]-loccur at l-or d-arginine concentrations considerably higher than those achieved in the present study [42] . Enhanced arginine in healthy human subjects. Although from their tracer studies Leaf et al. [55] calculated that below 0.1% of peripheral blood flow itself, as induced by (unspecific) vasodilation may increase endothelial NO release via the administered l-arginine dose were converted via NO to nitrate, Rhodes et al. [54] estimated that about 90% of elevating shear stress at the endothelial surface [43] .
Comparison of the AUC values for the oral or intravenous circulating nitrite is derived from the l-arginine5NO pathway in fasted humans. Taken together, these studies administration of 6 g l-arginine showed that the bioavailability of l-arginine is~70% after oral ingestion.
confirm that exogenous l-arginine acts as a substrate for NO synthesis in normal humans. Using stable-isotope-labeled l-arginine, Castillo et al. [44] also found incomplete bioavailability of orally ingested l-
The pharmacokinetic data generated in the present study provide evidence for dose-dependent pharmacokinetics of arginine (~38%). In contrast, Matera et al. [17] reported complete bioavailability of oral l-arginine in healthy humans.
l-arginine: With increasing dose, both the elimination halflife and the apparent volume of distribution decreased. One They administered in a very low daily dose (100 mg day −1 ), contained in a complex polyaminoacid formulation intended explanation for this observation may be a saturation of larginine uptake into cells by the highest dose (30 g). for use as an oral supplement in intensive care medicine, for 7 days. In the same study, these authors reported a terminal Extremely high plasma levels of l-arginine after this dose may have exceeded the renal threshold for l-arginine elimination half-life of~1.2 h, which is in agreement with our results obtained with considerably higher doses of lreabsorption, resulting in l-arginine overflow into the urine. In contrast to the 30 g dose of l-arginine, steady state was arginine. Half-life calculation in our study was somewhat hampered by the long time interval between the sampling reached during the infusion of 6 g of l-arginine, as indicated by the plateau of l-arginine plasma concentration during times at 210 and 960 min. This was caused by logistic reasons which did not allow us to keep the subjects in the the final 10 min of the infusion period. Therefore, the halflife calculated after the infusion of 6 g l-arginine may lab overnight. The significance of half life calculations was potentially reduced by this time pattern, but there is still a represent most closely the 'true' physiological half-life of this amino acid. Single doses of about 6 g l-arginine relatively close correspondence between our findings and those reported by others. Noeh et al. [45] studied tissue administered 2-3 times a day may be a reasonable approach to long-term studies with this amino acid for cardiovascular distribution of l-arginine in rats after intraperitoneal application; they found close correlation between the rise in disease.
In conclusion, our present study provides pharmacokinetic plasma arginine levels and arginine concentrations in NO-generating organs like aorta, heart, and vena cava. In data for l-arginine after intravenous and oral administration.
We have shown that the vascular effects of l-arginine in their study, l-arginine half-life was~1 h in plasma, and 1-2 h in the various tissues.
healthy human subjects are closely correlated with its plasma concentrations. These data may provide a basis for the 
